drugset / Trial / NCT00969163

A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED).

NCT00969163

Phase 1 Completed 30 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindDiagnostic

Summary

Postmenopausal women will receive testosterone gel or matching placebo gel daily. Sebum excretion rates will be measured before and after 6 weeks of treatment.

Timeline

Start
2004-10
Primary completion
2005-04
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 300 ug Other
Subject Testosterone Small molecule 2.5 mg Other

Indications

No indication recorded.